Search hospitals > Pennsylvania > Bryn Mawr
Bryn Mawr Hospital
Claim this profileBryn Mawr, Pennsylvania 19010
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Pancreatic Cancer
249 reported clinical trials
6 medical researchers
Summary
Bryn Mawr Hospital is a medical facility located in Bryn Mawr, Pennsylvania. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer and other specialties. Bryn Mawr Hospital is involved with conducting 249 clinical trials across 245 conditions. There are 6 research doctors associated with this hospital, such as Albert DeNittis, MD, Paul B. Gilman, Deric C. Savior, and John G. Devlin.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Albert DeNittis, MDLankenau Medical Center5 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
59 reported clinical trials
120 drugs studied
Paul B. GilmanRiddle Memorial Hospital4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
45 drugs studied
Deric C. SaviorPaoli Memorial Hospital11 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
27 drugs studied
John G. DevlinRiddle Memorial Hospital11 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
4 reported clinical trials
10 drugs studied
Clinical Trials running at Bryn Mawr Hospital
Lung Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Breast cancer
Cancer
Ovarian Cancer
Pancreatic Cancer
Uterine Cancer
Small Cell Lung Cancer
Endometrial Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting2 awards Phase 310 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Bryn Mawr Hospital?
Bryn Mawr Hospital is a medical facility located in Bryn Mawr, Pennsylvania. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer and other specialties. Bryn Mawr Hospital is involved with conducting 249 clinical trials across 245 conditions. There are 6 research doctors associated with this hospital, such as Albert DeNittis, MD, Paul B. Gilman, Deric C. Savior, and John G. Devlin.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.